ATE382365T1 - Thymosin-augmentation bei genetischer immunisierung - Google Patents

Thymosin-augmentation bei genetischer immunisierung

Info

Publication number: ATE382365T1
Authority: AT; Austria
Prior art keywords: hepatitis; virus; thymosine; augmentation; genetic immunization
Prior art date: 2001-10-26

Application number

AT02795564T

Other languages

English (en)

Inventor

Jack Wands

Original Assignee

Rhode Island Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-26

Filing date

2002-10-28

Publication date

2008-01-15

2002-10-28 Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital

2008-01-15 Application granted granted Critical

2008-01-15 Publication of ATE382365T1 publication Critical patent/ATE382365T1/de

Links

230000003053 immunization Effects 0.000 title abstract 3
230000003416 augmentation Effects 0.000 title 1
230000002068 genetic effect Effects 0.000 title 1
238000002649 immunization Methods 0.000 title 1
241000711549 Hepacivirus C Species 0.000 abstract 4
102000007501 Thymosin Human genes 0.000 abstract 3
108010046075 Thymosin Proteins 0.000 abstract 3
102000040430 polynucleotide Human genes 0.000 abstract 2
108091033319 polynucleotide Proteins 0.000 abstract 2
239000002157 polynucleotide Substances 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
230000024932 T cell mediated immunity Effects 0.000 abstract 1
208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Zoology (AREA)
Oncology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

AT02795564T 2001-10-26 2002-10-28 Thymosin-augmentation bei genetischer immunisierung ATE382365T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33063801P	2001-10-26	2001-10-26

Publications (1)

Publication Number	Publication Date
ATE382365T1 true ATE382365T1 (de)	2008-01-15

Family

ID=23290629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02795564T ATE382365T1 (de)	2001-10-26	2002-10-28	Thymosin-augmentation bei genetischer immunisierung

Country Status (21)

Country	Link
US (1)	US20050054845A1 (de)
EP (1)	EP1448223B1 (de)
JP (1)	JP2005506997A (de)
KR (1)	KR100902197B1 (de)
CN (1)	CN1269524C (de)
AT (1)	ATE382365T1 (de)
BR (1)	BR0213554A (de)
CA (1)	CA2464795A1 (de)
CY (1)	CY1107371T1 (de)
DE (1)	DE60224435T2 (de)
DK (1)	DK1448223T3 (de)
EA (1)	EA006743B1 (de)
ES (1)	ES2299626T3 (de)
IL (1)	IL161603A0 (de)
MX (1)	MXPA04003867A (de)
NO (1)	NO20042124L (de)
NZ (1)	NZ532863A (de)
PL (1)	PL370453A1 (de)
PT (1)	PT1448223E (de)
UA (1)	UA81613C2 (de)
WO (1)	WO2003035010A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006062917A2 (en) *	2004-12-06	2006-06-15	Sciclone Pharmaceuticals, Inc.	Alpha thymosin peptides as cancer vaccine adjuvants
JP2012526149A (ja) *	2009-05-08	2012-10-25	サイクローン・ファーマシューティカルズ・インコーポレイテッド	ワクチン増強剤としてのαチモシンペプチド

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4079127A (en) *	1976-10-28	1978-03-14	Board Of Regents Of The University Of Texas	Thymosin alpha 1
US4116951A (en) *	1977-04-22	1978-09-26	Hoffmann-La Roche Inc.	[Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) *	1978-01-23	1979-04-10	Hoffmann-La Roche Inc.	Synthesis of thymosin α1
DE2919592A1 (de) *	1979-05-15	1981-01-15	Max Planck Gesellschaft	Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
TW224053B (de) *	1991-09-13	1994-05-21	Paul B Chretien
US5620896A (en) *	1992-03-23	1997-04-15	University Of Massachusetts Medical Center	DNA vaccines against rotavirus infections
US5593972A (en) *	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
US6288033B1 (en) *	1998-09-25	2001-09-11	Sciclone Pharmaceuticals, Inc.	Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir

2002
- 2002-10-28 WO PCT/US2002/034535 patent/WO2003035010A2/en not_active Ceased
- 2002-10-28 PL PL02370453A patent/PL370453A1/xx unknown
- 2002-10-28 NZ NZ532863A patent/NZ532863A/en unknown
- 2002-10-28 JP JP2003537579A patent/JP2005506997A/ja active Pending
- 2002-10-28 EA EA200400534A patent/EA006743B1/ru not_active IP Right Cessation
- 2002-10-28 US US10/493,411 patent/US20050054845A1/en not_active Abandoned
- 2002-10-28 AT AT02795564T patent/ATE382365T1/de not_active IP Right Cessation
- 2002-10-28 UA UA20040503963A patent/UA81613C2/ru unknown
- 2002-10-28 PT PT02795564T patent/PT1448223E/pt unknown
- 2002-10-28 MX MXPA04003867A patent/MXPA04003867A/es active IP Right Grant
- 2002-10-28 CN CNB028212770A patent/CN1269524C/zh not_active Expired - Fee Related
- 2002-10-28 KR KR1020047006231A patent/KR100902197B1/ko not_active Expired - Fee Related
- 2002-10-28 IL IL16160302A patent/IL161603A0/xx unknown
- 2002-10-28 ES ES02795564T patent/ES2299626T3/es not_active Expired - Lifetime
- 2002-10-28 CA CA002464795A patent/CA2464795A1/en not_active Abandoned
- 2002-10-28 BR BR0213554-0A patent/BR0213554A/pt not_active IP Right Cessation
- 2002-10-28 DK DK02795564T patent/DK1448223T3/da active
- 2002-10-28 EP EP02795564A patent/EP1448223B1/de not_active Expired - Lifetime
- 2002-10-28 DE DE60224435T patent/DE60224435T2/de not_active Expired - Lifetime
2004
- 2004-05-24 NO NO20042124A patent/NO20042124L/no not_active Application Discontinuation
2008
- 2008-03-28 CY CY20081100354T patent/CY1107371T1/el unknown

Also Published As

Publication number	Publication date
JP2005506997A (ja)	2005-03-10
DE60224435D1 (de)	2008-02-14
BR0213554A (pt)	2004-10-26
EA006743B1 (ru)	2006-04-28
EP1448223B1 (de)	2008-01-02
IL161603A0 (en)	2004-09-27
PT1448223E (pt)	2008-01-23
EP1448223A2 (de)	2004-08-25
UA81613C2 (ru)	2008-01-25
MXPA04003867A (es)	2005-06-17
DK1448223T3 (da)	2008-02-18
CN1604789A (zh)	2005-04-06
EA200400534A1 (ru)	2004-12-30
ES2299626T3 (es)	2008-06-01
CA2464795A1 (en)	2003-05-01
KR20040089075A (ko)	2004-10-20
PL370453A1 (en)	2005-05-30
NZ532863A (en)	2006-07-28
WO2003035010A3 (en)	2003-12-04
KR100902197B1 (ko)	2009-06-11
EP1448223A4 (de)	2005-11-16
US20050054845A1 (en)	2005-03-10
NO20042124L (no)	2004-05-24
DE60224435T2 (de)	2009-01-02
WO2003035010A2 (en)	2003-05-01
CN1269524C (zh)	2006-08-16
CY1107371T1 (el)	2012-12-19

Legal Events

Date

Code

Title

Description

2008-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1448223

Country of ref document: EP

2010-07-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
WO2006041866A3 (en)	2006-09-08	Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
NZ319377A (en)	2000-01-28	polypeptides comprising a portion of a soluble M tuberculosis antigen
DK1090033T4 (da)	2008-03-31	Partikler af HCV-kappeproteiner: Anvendelse til vaccination
ATE466084T1 (de)	2010-05-15	Hla-a24-restringiertes krebsantigenpeptid
WO2005028496A3 (en)	2005-10-06	Vaccine for treatment and prevention of herpes simplex virus infection
MXPA05005203A (es)	2006-01-27	Vacuna contra vhc.
ATE551069T1 (de)	2012-04-15	Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
ATE458496T1 (de)	2010-03-15	Hiv-vakzine und anwendungsverfahren
DE69636285D1 (de)	2006-08-03	ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
DE60042816D1 (de)	2009-10-08	T-helferzellen-epitope
WO2001096370A3 (en)	2003-01-03	Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
MXPA05004804A (es)	2005-12-05	Antigenos de p153 y p156 para el inmunodiagnostico de erliquiosis canina y humana y usos de los mismos.
TW200641126A (en)	2006-12-01	N protein mutants of porcine reproductive and respiratory syndrome virus
MXPA06013388A (es)	2007-06-19	Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
DE60224435D1 (de)	2008-02-14	Thymosin-augmentation bei genetischer immunisierung
DK1301637T3 (da)	2008-09-29	DNA-vacciner, der koder for HIV accessoriske proteiner
WO2004058807A3 (en)	2004-09-30	Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
DK1578772T3 (da)	2010-08-16	Cytokiner og cytokinreceptorer med reduceret immunogenicitet
ATE476197T1 (de)	2010-08-15	Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
WO2002026785A3 (de)	2003-11-06	Cd4+ t-lymphozyten spezifische hepatitis c virus-epitope
DE69433057D1 (de)	2003-09-25	Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
ATE335507T1 (de)	2006-09-15	Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
AU2003208197A8 (en)	2003-09-16	Use of soluble fgl2 as an immunosuppressant
SE9600436D0 (sv)	1996-02-06	Vaccine against hantavirus
WO2006110881A3 (en)	2007-03-29	Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins